Similar Search Results

The contribution of pharmaceutical innovation to longevity growth in Germany and France

Lichtenberg, Frank R. - 2010

-adjusted mortality rates of residents of Germany, using longitudinal, annual, state-level data during the period 2000-2007. The estimates …-adjusted cancer mortality rates of residents of France, using longitudinal, annual, cancer-site-level data during the period 2002 … mortality rates, and may have accounted for as much as half of the decline. …

Persistent link: https://www.econbiz.de/10003977959

The global sanctions data base - release 3 : Covid-19, Russia and multilateral sanctions

Syropoulos, Constantinos; Felbermayr, Gabriel; … - 2022

This paper introduces the third update/release of the Global Sanctions Data Base (GSDB-R3). The GSDB-R3 extends the period of coverage from 1950-2019 to 1950-2022, which includes two special periods - COVID-19 and the war between Russia and Ukraine. The new update of the GSDB contains a total of...

Persistent link: https://www.econbiz.de/10013455750

Response to Baker and Fugh-Berman's critique of my paper, "Why has longevity increased more in some states than in others?"

Lichtenberg, Frank R. - 2009

study was subject to a number of major methodological flaws. Many of their claims pertain to the role of infant mortality …. I show that infant mortality was not an important determinant of the growth in U.S. life expectancy during the period … that I studied, and that my estimates are completely insensitive to the inclusion or exclusion of infant mortality …

Persistent link: https://www.econbiz.de/10003861794

The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010 : evidence from longitudinal, disease-level data

Lichtenberg, Frank R.; Pettersson, Billie - 2012

We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is estimated to have increased mean age at death by...

Persistent link: https://www.econbiz.de/10009571756

Sources of US longevity increase, 1960 - 1997

Lichtenberg, Frank R. - 2000

Between 1960 and 1997, life expectancy at birth of Americans increased approximately 10% G from 69.7 to 76.5 years G and it has been estimated that the value of life extension during this period nearly equaled the gains in tangible consumption. While life expectancy has tended to increase, there...

Persistent link: https://www.econbiz.de/10011397757

The impact of recent chemotherapy innovation on the longevity of Myeloma patients : U.S. and international evidence

Lichtenberg, Frank R.; Hostenkamp, Gisela - 2013

myeloma mortality rate using longitudinal country-level data on 26 countries during the period 2005-2009. Countries that had … larger increases in the number of chemotherapy regimens had larger subsequent declines in myeloma mortality rates …, controlling for other factors. The estimates imply that chemotherapy innovation reduced the age-adjusted myeloma cancer mortality …

Persistent link: https://www.econbiz.de/10010223067

The impact of new drug launches on hospitalization in 2015 for 67 medical conditions in 15 OECD countries : a two-way fixed-effects analysis

Lichtenberg, Frank R. - 2019

There are two types of prescription drug cost offsets. The first type of cost offset - from prescription drug use - is primarily about the effect of changes in drug quantity (e.g. due to changes in out-of-pocket drug costs) on other medical costs. The second type of cost offset - the cost offset...

Persistent link: https://www.econbiz.de/10011987056

Market access through bound tariffs

Sala, Davide; Schröder, Philipp J. H.; Yalçin, Erdal - 2009

WTO negotiations deal predominantly with bound - besides applied - tariff rates. But, how can reductions in tariffs ceilings, i.e. tariff rates that no exporter may ever actually be confronted with, generate market access? The answer to this question relates to the effects of tariff bindings on...

Persistent link: https://www.econbiz.de/10003910492

Quantifying the economic effects of an EU-Japan free trade agreement

Benz, Sebastian; Yalçin, Erdal - 2013

The European Union and Japan have recently launched negotiations about a bilateral free trade agreement as means of economic stimulation, with trade as a driving force to create growth and wealth. Since customs duties are already low, the success of the liberalization process hinges on the...

Persistent link: https://www.econbiz.de/10009764931

Mitigating liquidity constraints : public export credit guarantees in Germany

Felbermayr, Gabriel; Heiland, Inga; Yalçin, Erdal - 2012

Reportedly, firms often find it impossible to finance large and long-term projects despite positive net present values. Should governments step in and can their assistance be effective? This paper studies the case of public export credit guarantees in Germany. Covering the default risk of...

Persistent link: https://www.econbiz.de/10009580766